BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

363 related articles for article (PubMed ID: 16441423)

  • 1. Immunohistochemical and genetic features of gastric and metastatic liver gastrointestinal stromal tumors: sequential analyses.
    Kikuchi H; Yamashita K; Kawabata T; Yamamoto M; Hiramatsu Y; Kondo K; Baba M; Ohta M; Kamiya K; Tanaka T; Suzuki S; Kitagawa K; Kitagawa M; Sugimura H; Konno H
    Cancer Sci; 2006 Feb; 97(2):127-32. PubMed ID: 16441423
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of loss of heterozygosity of the c-kit gene on prognosis after hepatectomy for metastatic liver gastrointestinal stromal tumors.
    Kikuchi H; Yamamoto M; Hiramatsu Y; Baba M; Ohta M; Kamiya K; Tanaka T; Suzuki S; Sugimura H; Kitagawa M; Kanai T; Kitayama Y; Kanda T; Nishikura K; Konno H
    Cancer Sci; 2007 Nov; 98(11):1734-9. PubMed ID: 17894554
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Microarray analysis identifies versican and CD9 as potent prognostic markers in gastric gastrointestinal stromal tumors.
    Setoguchi T; Kikuchi H; Yamamoto M; Baba M; Ohta M; Kamiya K; Tanaka T; Baba S; Goto-Inoue N; Setou M; Sasaki T; Mori H; Sugimura H; Konno H
    Cancer Sci; 2011 Apr; 102(4):883-9. PubMed ID: 21244575
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapeutic consequences from molecular biology for gastrointestinal stromal tumor patients affected by neurofibromatosis type 1.
    Mussi C; Schildhaus HU; Gronchi A; Wardelmann E; Hohenberger P
    Clin Cancer Res; 2008 Jul; 14(14):4550-5. PubMed ID: 18628470
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [New orientations in the management of advanced, metastatic gastrointestinal stromal tumors (GIST): combination of surgery and systemic therapy with imatinib in a case of primary gastric location].
    Catani M; De Milito R; Simi M
    Chir Ital; 2005; 57(1):127-33. PubMed ID: 15832750
    [TBL] [Abstract][Full Text] [Related]  

  • 6. c-Kit/PDGFRA gene status alterations possibly related to primary imatinib resistance in gastrointestinal stromal tumors.
    Miselli FC; Casieri P; Negri T; Orsenigo M; Lagonigro MS; Gronchi A; Fiore M; Casali PG; Bertulli R; Carbone A; Pierotti MA; Tamborini E; Pilotti S
    Clin Cancer Res; 2007 Apr; 13(8):2369-77. PubMed ID: 17438095
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pathology of gastrointestinal stromal tumors.
    Hirota S; Isozaki K
    Pathol Int; 2006 Jan; 56(1):1-9. PubMed ID: 16398673
    [TBL] [Abstract][Full Text] [Related]  

  • 8. KIT immunohistochemistry and mutation status in gastrointestinal stromal tumours (GISTs) evaluated for treatment with imatinib.
    Loughrey MB; Trivett M; Beshay V; Dobrovic A; Kovalenko S; Murray W; Lade S; Turner H; McArthur GA; Zalcberg J; Waring PM
    Histopathology; 2006 Jul; 49(1):52-65. PubMed ID: 16842246
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Decrease of CD117 expression as possible prognostic marker for recurrence in the resected specimen after imatinib treatment in patients with initially unresectable gastrointestinal stromal tumors: a clinicopathological analysis.
    Mearadji A; den Bakker MA; van Geel AN; Eggermont AM; Sleijfer S; Verweij J; de Wilt JH; Verhoef C
    Anticancer Drugs; 2008 Jul; 19(6):607-12. PubMed ID: 18525320
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Minute gastric sclerosing stromal tumors (GIST tumorlets) are common in adults and frequently show c-KIT mutations.
    Agaimy A; Wünsch PH; Hofstaedter F; Blaszyk H; Rümmele P; Gaumann A; Dietmaier W; Hartmann A
    Am J Surg Pathol; 2007 Jan; 31(1):113-20. PubMed ID: 17197927
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Correlation of immunophenotype with progression-free survival in patients with gastrointestinal stromal tumors treated with imatinib mesylate.
    Chirieac LR; Trent JC; Steinert DM; Choi H; Yang Y; Zhang J; Patel SR; Benjamin RS; Raymond AK
    Cancer; 2006 Nov; 107(9):2237-44. PubMed ID: 16998931
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gastrointestinal stromal tumors presenting as omental masses--a clinicopathologic analysis of 95 cases.
    Miettinen M; Sobin LH; Lasota J
    Am J Surg Pathol; 2009 Sep; 33(9):1267-75. PubMed ID: 19440146
    [TBL] [Abstract][Full Text] [Related]  

  • 13. "Pediatric-type" gastrointestinal stromal tumors in adults: distinctive histology predicts genotype and clinical behavior.
    Rege TA; Wagner AJ; Corless CL; Heinrich MC; Hornick JL
    Am J Surg Pathol; 2011 Apr; 35(4):495-504. PubMed ID: 21358303
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Changing phenotype of gastrointestinal stromal tumours under imatinib mesylate treatment: a potential diagnostic pitfall.
    Pauwels P; Debiec-Rychter M; Stul M; De Wever I; Van Oosterom AT; Sciot R
    Histopathology; 2005 Jul; 47(1):41-7. PubMed ID: 15982322
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rhabdomyosarcomatous differentiation in gastrointestinal stromal tumors after tyrosine kinase inhibitor therapy: a novel form of tumor progression.
    Liegl B; Hornick JL; Antonescu CR; Corless CL; Fletcher CD
    Am J Surg Pathol; 2009 Feb; 33(2):218-26. PubMed ID: 18830121
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Polyclonal evolution of multiple secondary KIT mutations in gastrointestinal stromal tumors under treatment with imatinib mesylate.
    Wardelmann E; Merkelbach-Bruse S; Pauls K; Thomas N; Schildhaus HU; Heinicke T; Speidel N; Pietsch T; Buettner R; Pink D; Reichardt P; Hohenberger P
    Clin Cancer Res; 2006 Mar; 12(6):1743-9. PubMed ID: 16551858
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Different factors are responsible for predicting relapses after primary tumors resection and for imatinib treatment outcomes in gastrointestinal stromal tumors.
    Rutkowski P; Debiec-Rychter M; Nowecki ZI; Wozniak A; Michej W; Limon J; Siedlecki JA; Jerzak Vel Dobosz A; Grzesiakowska U; Nasierowska-Guttmejer A; Sygut J; Nyckowski P; Krawczyk M; Ruka W
    Med Sci Monit; 2007 Nov; 13(11):CR515-522. PubMed ID: 17968300
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pleomorphic phenotypes of gastrointestinal stromal tumors at metastatic sites with or without imatinib treatment.
    Sakamoto K; Sakurai S; Kanda T; Sakuma Y; Hishima T; Hironaka M; Bamba T; Keira Y; Takano Y; Niki T; Hasegawa T; Hirota S
    Cancer Sci; 2010 May; 101(5):1270-8. PubMed ID: 20180814
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Two cases of gastrointestinal stromal tumor of the stomach with lymph node metastasis.
    Sato T; Kanda T; Nishikura K; Hirota S; Hashimoto K; Nahagawa S; Ohashi M; Hatakeyama K
    Hepatogastroenterology; 2007 Jun; 54(76):1057-60. PubMed ID: 17629038
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multiple sporadic gastrointestinal stromal tumors (GISTs) of the proximal stomach are caused by different somatic KIT mutations suggesting a field effect.
    Agaimy A; Dirnhofer S; Wünsch PH; Terracciano LM; Tornillo L; Bihl MP
    Am J Surg Pathol; 2008 Oct; 32(10):1553-9. PubMed ID: 18724245
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.